{"@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{"@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.patentleaderboard.com/"}, {"@type": "ListItem", "position": 2, "name": "CTLA-4 antibody dosage escalation regimens", "item": "https://www.patentleaderboard.com/patent/9573999"}]}
Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › CTLA-4 antibody dosage escalation regimens

CTLA-4 antibody dosage escalation regimens

US Patent 9573999 · Granted Feb 21, 2017

Estimated economic value: $698,697,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Intralesional administration of PD-1 inhibitors for treating skin cancer2025
Combination therapy to treat brain cancer2025
Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies2024
Anti-PD-1 antibodies for treatment of lung cancer2024
Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibo2024
Dosing strategy that mitigates cytokine release syndrome for therapeutic antibod2023
Methods of treating skin cancer by administering a PD-1 inhibitor2022
Anti-angiogenic therapy of metastatic colorectal cancer2022
Anti-PD-1 antibodies for treatment of lung cancer2022
Methods for tumor treatment using CD3XCD20 bispecific antibody2020
B cell lineage based immunogen design with humanized animals2020
Methods and compositions comprising a combination of a VEGF antagonist and an an2020